IAM Issue 34

Standardising IP valuations: whether, what and how

Valuing IP is complex, with more
than 50 different methods currently
in use. Given the growing
importance of IP to so many
organisations, perhaps now is the
time to re-think whether global
valuation standards make sense

Patrick Sullivan


Small is beautiful

Cellport Systems has thrived as a
small research-based business in a
market dominated by the big boys.
An innovative approach to patenting
plays a fundamental role in a
strategy that has created several
billion-dollar revenue streams

The patent transaction market at a crossroads

There has never been a better time
to acquire high-quality patents at
low prices. Companies and other
entities should be taking advantage
of this fact

Managing IP in a difficult economic environment

There are proven ways to reduce IP
investment costs while also
enhancing the value of rights
portfolios. During an economic
downturn, these come into their own

Measuring and conveying IP value the HP way

Hewlett-Packard has devoted
significant time and resources to
ensuring that its IP portfolio is
aligned to the company’s overall
strategic goals. An extract from a
recently published book* about IP
business models explains how

The reputation and intangible asset value crash of 2008

Over the last 12 to 18 months the
percentage of listed company
values that can be attributed to
intangibles has fallen rapidly, to
stand at under 50%. Serious
rebuilding work is needed

Business models, value chains and value propositions

To create maximum value from
intellectual property rights, owners
have to ensure that their IP
management and business
strategies are closely aligned


CIPO forumExamining re-exams: part two

Inter partes re-examinations at the
USPTO could play a part in reducing
patent values and discouraging R&D

IP lawyerNo confusion – less joy for trademark owners

In one of its first considerations of
dilution, the ECJ delivered a judgment
that makes it a difficult concept for
trademark owners to claim

The intellectual capitalistThe highest form of flattery

The modern-day debate about IP is often
described as polarised and ideological.
Unfortunately, this may be too kind.
Many views are best described as naïve
and manipulative. The discourse on
counterfeiting and piracy is a good case
in point

IP investorYours, mine, ours

A new book claims that strong patentholder
rights undermine social and
business objectives, and waste valuable

Management report

How does your licence agreement address timely issues?

Licensing deals are negotiated and
licensing agreements written in real
time. A robust pro forma licence
agreement can save hours of
transaction time at critical points in
a deal

The Indian version of the Bayh-Dole Act

A bill that would allow governmentfunded
academic institutions to
patent their inventions has received
a mixed reception. It should result in
greater interaction between
industry, academia and
government, but some fear it does
not protect the public interest

Options available when commercialising university IP

By implementing a sound and
flexible IP management process,
universities can spot the
technologies most suitable for
exploitation and give them a good
start in life. For those that do so,
there are rich rewards to be reaped

The truth about business method patents

Business method patents are still
alive and well in the United States.
However, the Federal Circuit’s
landmark Bilski decision is a
reminder that they must meet the
“machine-or-transformation” test,
like any other process claim.


Sometimes it’s best to look outside of the IP bubble

A background in IP is not a
prerequisite for patent and
trademark office bosses in
most jurisdictions; it should not
be in the United States either

Industry insight

How law firms can get a competitive edge in 2009 and beyond

In today’s economic environment, it is
essential for law firms, like most other
businesses, to distinguish themselves
from their competitors in order to
maintain and grow market share, says
Steve Kriston, director of North American
sales for the Scientific business of
Thomson Reuters